Stock Market Reviews

KALA (KALA BIO, Inc.) News

Get the latest news, insights, and market updates on KALA (KALA BIO, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint
  -- Study did not meet primary endpoint of complete healing of PCED at Week 8; secondary endpoints also did not achieve statistical significance -- -- KPI-012 was well-tolerated with no treatment-related serious adverse events observed -- -- KALA to cease clinical development of KPI-012, preserve cash and explore strategic options -- ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development
  Sep 29, 2025 - $KALA
• KALA BIO, Inc.'s (NASDAQ:KALA) market cap surged US$28m last week, retail investors who have a lot riding on the company were rewarded
  Key Insights Significant control over KALA BIO by retail investors implies that the general public has more power to...
  Sep 5, 2025 - $KALA
• KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
  ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 27th Annual Global Investment Conference being held in New York, NY on Wednesday, September 10, 2025 at 2:00 p.m. ET. Management will be available for one-on-one meeting
  Sep 3, 2025 - $KALA
• KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director
  Mr. Bazemore brings over 30 years of extensive leadership experience in the biopharmaceutical industry with a focus on growing rare disease companiesARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KA
  Sep 2, 2025 - $KALA
• Wall Street Analysts Believe KALA BIO (KALA) Could Rally 74.73%: Here's is How to Trade
  The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Aug 13, 2025 - $KALA
• KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update
  -- Completed patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data expected at the end of September 2025 -- -- Cash resources of $31.9 million as of June 30, 2025, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., Aug. 08, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe d
  Aug 8, 2025 - $KALA
• KALA BIO: Q2 Earnings Snapshot
  ARLINGTON, Mass. AP) — KALA BIO, Inc. KALA) on Friday reported a loss of $11.2 million in its second quarter.
  Aug 8, 2025 - $KALA
• KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
  ARLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference being held virtually on Wednesday, August 13, 2025. A pre-recorded presentation will be made available beginning on Wednesday,
  Aug 6, 2025 - $KALA
• Zacks.com featured highlights include KALA, Graham, Arq and Hawkins
  KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.
  Jul 28, 2025 - $KALA
• Analyst Coverage Sparks Interest in These 4 Stocks Amid Volatility
  New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.
  Jul 25, 2025 - $KALA